Dual dose-dependent effects of fingolimod in a mouse model of Alzheimer’s disease
Author:
Publisher
Springer Science and Business Media LLC
Subject
Multidisciplinary
Link
http://www.nature.com/articles/s41598-019-47287-1.pdf
Reference65 articles.
1. He, X., Huang, Y., Li, B., Gong, C. X. & Schuchman, E. H. Deregulation of sphingolipid metabolism in Alzheimer’s disease. Neurobiol Aging 31, 398–408, https://doi.org/10.1016/j.neurobiolaging.2008.05.010 (2010).
2. Couttas, T. A. et al. Loss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimer’s disease pathogenesis. Acta Neuropathol Commun 2, 9, https://doi.org/10.1186/2051-5960-2-9 (2014).
3. Katsel, P., Li, C. & Haroutunian, V. Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer’s disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer’s disease? Neurochem Res 32, 845-–856, https://doi.org/10.1007/s11064-007-9297-x (2007).
4. Fyrst, H. & Saba, J. D. An update on sphingosine-1-phosphate and other sphingolipid mediators. Nature chemical biology 6, 489–497, https://doi.org/10.1038/nchembio.392 (2010).
5. Blaho, V. A. & Hla, T. An update on the biology of sphingosine 1-phosphate receptors. J Lipid Res 55, 1596–1608, https://doi.org/10.1194/jlr.R046300 (2014).
Cited by 42 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Therapeutic Potential of Fingolimod on Psychological Symptoms and Cognitive Function in Neuropsychiatric and Neurological Disorders;Neurochemical Research;2024-06-26
2. S1PR2 inhibition mitigates cognitive deficit in diabetic mice by modulating microglial activation via Akt-p53-TIGAR pathway;International Immunopharmacology;2024-01
3. The S1P receptor 1 antagonist Ponesimod reduces TLR4-induced neuroinflammation and increases Aβ clearance in 5XFAD mice;eBioMedicine;2023-08
4. Molecular and neuroimmune pharmacology of S1P receptor modulators and other disease-modifying therapies for multiple sclerosis;Pharmacology & Therapeutics;2023-06
5. A Phase 1 First‐in‐Human Single‐Ascending‐Dose Trial With ESB1609, a Selective Agonist to the Sphingosine‐1‐Phosphate Receptor 5;Clinical Pharmacology in Drug Development;2023-05-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3